Monoclonal Antibodies In Veterinary Health Market Analysis Through 2030 Focusing On Demand Trends And Growth Drivers
The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Is The Expected Market Size Of The Monoclonal Antibodies In Veterinary Health Market In 2026 And How Much Will It Reach By 2030?
The monoclonal antibodies in veterinary health market has experienced substantial growth in recent years. It is forecast to rise from $0.92 billion in 2025 to $1.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. The expansion observed historically can be ascribed to the rising prevalence of canine cancers, an increasing incidence of autoimmune disorders in pets, the limited availability of targeted therapies, the growth of veterinary hospitals, and a greater awareness of advanced veterinary treatments.
The monoclonal antibodies in veterinary health market is projected for significant expansion in the coming years, anticipated to reach $1.85 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.8%. Several factors will drive this growth during the forecast period, including advancements in mAb engineering technology, a greater uptake of species-specific treatments, increased investment in veterinary oncology and dermatology fields, the evolution of personalized veterinary medicine, and the expansion of the global veterinary healthcare infrastructure. Key trends foreseen for the forecast period encompass an increase in monoclonal antibody-based treatments for canine cancer, a surge in the application of mAbs for autoimmune conditions in dogs, broader use of veterinary dermatology applications, enhanced adoption of targeted pain management solutions, and the creation of species-specific antibody therapies tailored for cats, horses, and livestock.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp
What Key Growth Drivers Are Influencing The Monoclonal Antibodies In Veterinary Health Market?
The rising animal disease incidences are expected to propel the growth of the monoclonal antibodies in veterinary health market going forward. The rising incidence of animal diseases is driven by intensified farming practices, which increase the risk of infectious disease spread, and climate change, which expands the range of disease vectors such as ticks and mosquitoes. Monoclonal antibodies are highly useful for treating animal diseases as they target specific pathogens or proteins involved in disease processes, offering precise and effective treatments. For instance, in June 2024, according to a report published by the GOV.UK, a UK-based government website, between April 2023 and March 2024, the number of animals slaughtered due to TB incidents rose by 5% in England to 21,298, and by 17% in Wales to 11,197. The rising animal disease incidences are driving the growth of monoclonal antibodies in veterinary health market.
How Is The Monoclonal Antibodies In Veterinary Health Market Examined Through Segment Analysis?
The monoclonal antibodies in veterinary health market covered in this report is segmented –
1) By Product: Monoclonal Antibodies (mAbs), Glucocorticoids, Antihistamines, Immunosuppressants, Other Products
2) By Animal Type: Dogs, Cats, Horses, Livestock, Other Animals
3) By Indication: Allergic Skin Disease, Autoimmune Disorders, Infectious Diseases, Cancer Or Tumor Therapy, Other Indications
4) By Route Of Administration: Injectable, Oral, Topical
5) By Distribution Channel: Veterinary Clinics, Specialized Animal Hospitals, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Lokivetmab, Felvetmab, Investigational Monoclonal Antibodies, Equine-specific mAbs
2) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone
3) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine
4) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil
5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics
What Trends Are Shaping The Monoclonal Antibodies In Veterinary Health Market Structure?
Major companies operating in the monoclonal antibodies in veterinary health market are focusing on developing innovative veterinary therapeutic solutions, such as anti-NGF monoclonal antibody treatment to address conditions such as chronic pain and inflammation in animals. Anti-NGF monoclonal antibody treatment refers to a therapeutic approach that targets and inhibits nerve growth factor (NGF) to reduce pain and inflammation in animals suffering from chronic pain conditions. For instance, in May 2023, Zoetis, a US-based animal health company, received FDA approvals for Librela (bedinvetmab injection), the first monoclonal antibody treatment for controlling pain associated with osteoarthritis (OA) in dogs, which is administered as a once-monthly injection, and Apoquel Chewable, the first chewable medication specifically for managing allergic itch and inflammation in dogs aged one year or older. Librela is a monoclonal antibody that targets and inhibits nerve growth factor (NGF). By blocking NGF, Librela helps to prevent these pain signals from reaching the brain, thereby reducing the sensation of pain in dogs with osteoarthritis. Librela represents a significant advancement in veterinary pain management, providing a novel approach to treating chronic pain in dogs.
Which Companies Are Influencing The Monoclonal Antibodies In Veterinary Health Market?
North America was the largest region in the monoclonal antibodies in veterinary health market in 2025. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access The Complete Monoclonal Antibodies In Veterinary Health Market Report:
Which Geographic Region Represents The Largest Monoclonal Antibodies In Veterinary Health Market Share?
North America was the largest region in the monoclonal antibodies in veterinary health market in 2025. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Customized Monoclonal Antibodies In Veterinary Health Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
